Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Rna Diagnostics Inc. logo — company profile

Rna Diagnostics Inc.

Founded 2010 10 employees Series A Total: $6.73M Health Care

General Information

Company Name Rna Diagnostics Inc.
Founded Year 2010
Employees 10
Industries Health Care
Funding Stage Series A
Social

Get notified when Rna Diagnostics Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Rna Diagnostics Inc.

Rna Diagnostics Inc. is a clinical stage molecular diagnostics company specializing in personalized cancer therapy management. The company's Veridapt DX™ predictive biomarker platform technology, currently in clinical trials, aims to measure early solid tumor response to neoadjuvant cancer treatment by identifying non-responsive solid tumors through the monitoring of RNA disruption in the cells. This technology has the potential to significantly impact cancer treatment by enabling physicians to make informed decisions about treatment escalation or de-escalation, or alternative strategies, as early as 5 weeks into a 6-month treatment regimen. The company has garnered significant attention through a Phase 1 study published in JNCI Cancer Spectrum, which demonstrated the strong capability of Veridapt DX with a Negative Predictive Value of over 93% in predicting therapy efficacy/outcomes during early treatment. Following this, Phase 2 trials are currently ongoing in 7 countries, adding to the company's growing body of evidence for clinical effectiveness. Rna Diagnostics Inc. has positioned itself as a potential game-changer in cancer treatment, with a specific focus on primary breast cancer management through the ongoing BREVITY clinical trial. However, the company emphasizes the broader applicability of its assay platform to any solid tumor and any cancer drug therapy, signaling a significant market potential for personalized, precision medicine. Notably, the company secured a Series A investment from MEDTEQ+ in July 2019, indicating investor confidence in the company's innovative approach to improving cancer treatment. Additionally, the company's proactive stance on collaborative trials for early assessment of treatment for solid tumor cancers underscores its commitment to advancing cancer care.

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 1
Investor
26 Jul 2019
Series A •••••• 1
Investor
09 Nov 2018
Angel Round •••••• 3
Investor Investor Investor
15 Jan 2016
Angel Round •••••• - 21 Sep 2015
Angel Round •••••• 5
Investor Investor Investor
•••• •••• 		27 Mar 2012

Rna Diagnostics Inc. Alternatives & Competitors

Rna Diagnostics Inc. vs
BioMarker Strategies, LLC
BioMarker Strategies, LLC United States

BioMarker Strategies has developed the proprietary SnapPath® Cancer Diagnostics System for predictiv...

Series Unknown
5 employees
Biotechnology, Health Care
Rna Diagnostics Inc. vs
Genekor Medical S.A.
Genekor Medical S.A. Greece

Committed to Biotechnological Innovation.

88 employees
Biotechnology, Health Care

FAQ About Rna Diagnostics Inc.

Rna Diagnostics Inc. is a clinical stage molecular diagnostics company for personalized cancer therapy management. We are working with physicians around the globe to improve cancer treatment and the quality of life for patients, while reducing healthcare costs. Our predictive biomarker platform t...
Rna Diagnostics Inc. was founded in 2010.
Rna Diagnostics Inc. operates in the following industries: Health Care.
Rna Diagnostics Inc. has approximately 10 employees.
Rna Diagnostics Inc. has completed 5 funding rounds, raising a total of $6.73M. The latest funding stage is Series A.
Top alternatives and competitors to Rna Diagnostics Inc. include BioMarker Strategies, LLC, Genekor Medical S.A.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Rna Diagnostics Inc. and BioMarker Strategies, LLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Rna Diagnostics Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy